Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Jeff CisliniSVP & General Counsel | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 09/25 | 09/29 | 765 sh | $207.32 | $158,599.88 | −1.5% |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 09/24–09/25 | 09/28 | 3,708 sh2 trades | $200.45avg. | $743,285.34 | −8.5% | |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 09/22 | 09/24 | 10,143 sh5 trades | $193.04avg. | $1,958,015.88 | −70.1% | |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 06/24 | 06/26 | 20,000 sh4 trades | $168.33avg. | $3,366,642.99 | −14.0% | |
Mark A. GoldsmithSEE REMARKS | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 06/16 | 06/18 | 10,020 sh | $156.12 | $1,564,322.4 | −3.6% |
Stephen Michael KelseySEE REMARKS | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 06/16 | 06/18 | 4,175 sh | $156.12 | $651,801 | −1.4% |
Jack AndersCFO | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 06/16 | 06/18 | 2,722 sh | $156.12 | $424,958.64 | −2.2% |
Jeff CisliniGeneral Counsel | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 06/16 | 06/18 | 2,157 sh | $156.12 | $336,750.84 | −3.7% |
Anthony ManciniSEE REMARKS | Revolution MedicinesRVMD | Open-market sale | 06/16 | 06/18 | 4,615 sh | $156.12 | $720,493.8 | −8.5% |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 25/06/16–06/17 | 06/17 | 93,575 sh3 trades | $160.00avg. | $14,971,949 | −37.7% | |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 06/11 | 06/15 | 10,000 sh7 trades | $148.01avg. | $1,480,122.95 | −5.9% | |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 05/26 | 05/28 | 3,121 sh3 trades | $153.99avg. | $480,609.22 | −5.4% | |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 04/27 | 04/29 | 3,120 sh3 trades | $132.41avg. | $413,130.98 | −5.4% | |
Mark A. GoldsmithSEE REMARKS | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 04/15 | 04/17 | 120,000 sh | $150.09 | $18,010,800 | −30.2% |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 03/25 | 03/26 | 37,450 sh5 trades | $95.57avg. | $3,578,916.1 | −40.8% | |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 03/17–03/19 | 03/19 | 2,958 sh2 trades | $98.68avg. | $291,889.32 | −4.8% | |
Mark A. GoldsmithSEE REMARKS | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 03/17 | 03/19 | 12,871 sh | $99.48 | $1,280,407.08 | −4.4% |
Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 03/17 | 03/19 | 4,583 sh | $99.48 | $455,916.84 | −2.8% | |
Stephen Michael KelseySEE REMARKS | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 03/17 | 03/19 | 4,302 sh | $99.48 | $427,962.96 | −1.4% |
Jack AndersCFO | Revolution MedicinesRVMD | Open-market sale10b5-1 plan | 03/17 | 03/19 | 2,753 sh | $99.48 | $273,868.44 | −2.1% |